Heron Therapeutics (NASDAQ:HRTX) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Thursday, January 24th.
HRTX has been the topic of several other reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $64.00 target price (down from $66.00) on shares of Heron Therapeutics in a research note on Wednesday, January 16th. Cantor Fitzgerald set a $50.00 target price on shares of Heron Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, October 30th. Zacks Investment Research downgraded shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 9th. Finally, ValuEngine raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and twelve have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $51.91.
Shares of Heron Therapeutics stock opened at $27.22 on Thursday. Heron Therapeutics has a 52-week low of $19.55 and a 52-week high of $42.90. The company has a market capitalization of $2.12 billion, a PE ratio of 7.46 and a beta of 1.64.
About Heron Therapeutics
Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Featured Story: Why is the conference call important?
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.